Cannabidiol oral solution — Competitive Intelligence Brief

Cannabidiol oral solution (Cannabidiol oral solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology.

phase 3 Cannabinoid Multiple targets including TRPV1, 5-HT1A, GPR55, and endocannabinoid system modulation Neurology Small molecule

Target snapshot

Cannabidiol oral solution (Cannabidiol oral solution) — University of California, San Diego. Cannabidiol modulates endocannabinoid signaling and multiple other pathways to reduce seizure activity and provide neuroprotective effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cannabidiol oral solution TARGET	Cannabidiol oral solution	University of California, San Diego	phase 3	Cannabinoid	Multiple targets including TRPV1, 5-HT1A, GPR55, and endocannabinoid system modulation
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01
Marinol	DRONABINOL	Wellhouse Pharma	marketed	Cannabinoid [EPC]	Cannabinoid receptors	1985-01-01
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

1. Wayne State University · 3 drugs in this class
2. Hôpital le Vinatier · 1 drug in this class
3. Montefiore Medical Center · 1 drug in this class
4. OMNI Medical Services, LLC · 1 drug in this class
5. Gold Coast Hospital and Health Service · 1 drug in this class
6. Stero Biotechs Ltd. · 1 drug in this class
7. University of California, San Diego · 1 drug in this class
8. University of Connecticut · 1 drug in this class
9. Staci Gruber, Ph.D. · 1 drug in this class